Lupin Ltd — Capital/Financing Update 2021

Dec 2, 2021

December 2. 2021

Umfted Department of Corporate Services, P. J. Towers, Dalal Street, Mumbai Samachar Marg, MUMBAI - 400 001.

National Stock Exchange of lndla Limited Exchange Plaza, Sandra Kurla Complex, Bandra (East), MUMBAI - 400 05].

Sub: Dlsclosure pursuant to RtaulaHon 30 of th• SEBI CUstlnq Obllaatlons and plsclosure Requirements) Regulatlons. 2015.

Dear Sir/Madam,

Enclosed is a Press Release as regards the Company having entered Into an agreement with TIP pie (The Technology Partnership pie) to acquire the exclusive worldwide rights to develop, manufacture and commercialize inhalation products using TTP's soft-mist inhalation technology platform.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

FOii WPIN LIMITED

•

R.Y.BATAM lvv COMPANYSECRETARY (ACS-t! 873)

Encl-: a/a.

LUPIN LIMITED

Lupin Partners with lTP pie UK for Soft-mist Inhalation Technology Platform

Mumbai, Somerset, New Jersey, December 02, 2021: Lupin Inc., a wholly-owned subsidiary of global pharma major, Lupin Limited (Lupin) has entered into an agreement with TTP pie (The Technology Partnership pie) to acquire. the exclusive worldwide rights to develop, manufacture and commercialize Inhalation products using TTP's soft-mist inhalation technology platform. By leveraging this technology, Lupin expects to provide healthcare professionals with alternative solutions for delivering affordable Inhaled medicines to patients across the globe.

Soft-mist inhalation (SMI) technology allows for delivery of inhalatlon drugs from a small, portable hand-held inhaler device without the use of propellants. The individual doses are delivered using a precisely engineered nozzle system to produce a slow-moving and long-sustaining aerosol cloud. Lupin anticipates applications across respiratory care.

Lupin and TTP will jointly develop the device. Lupin will commercially manufacture the device through its network of in-house and external manufacturing locations. Lupin will also develop and manufacture formulations to be delivered through the device, obtain the necessary regulatory approvals, and commercialize the products globally.

Commenting on the development Vinita Gupta, Global CEO, Lupin said, "Inhalation is a strategic pillar of Lu pin's growth story, as we strive to bring affordable medicines to patients across the globe. The partnership with TTP for SMI technology platform Is a strategic addition to our broad Inhalation capab ilitles."

Alok Sonia, CEO- US Generics & Global RAD Head, Lupin added, "Lupin is excited to be partnering with TTP. The organizations will work together to develop products using TIP's SMI technology that complement Lu pin's portfolio of complex inhalation products."

Commenting on the development, Sam Hyde, Managing Director, TTP said, "We are excited to be partnering with Lupin to commercialize our SMI technology so that it can benefit patients suffering with chronic respiratory conditions. TIP has deep expertise In aerosol science, and we have been working with our clients for over 30 years in complex drug delivery device development - this partnership represents an exciting next step for us in this innovative area of respiratory drug · delivery."

----

About Lupin

lupin Is an Innovation-led transnational pharmaceutical company headquartered In Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APls in over 100 markets In the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions . .

The Company enjoys leadership position In the.cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of Its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research' centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupln.com for more information. Follow us on Twitter: www.twitter.com/LuplnGJobal I Linked In: www.linkedin.com/companv/lupln/ Facebook: www.facebook.com/ Lul!.inWodd/

AboutTTP

TTP is an Independent technology company where scientists, engineers, and desisners collaborate to Invent, design and develop new products and technologies. With a 30-year history of invention, its multidisciplinary teams are able to deliver across the scope of a project, from research through to ideas, design, engineering and manufacture.

TTP's state-of-the-art technical facilities are part of Europe's largest technology hub in Cambridge, UK. Here, it works across a wide spectrum of Industries - Including healthcare, telecoms, Industrials and consumer - to create breakthrough solutions that bring strong com me rcla I value to clients and the ben eflts of technology to all. TTP has a long history in drug delivery device development and deep expertise in the science, engineering and manufacture of controlled droplet generation technolosies.

Please visit www.ttp.com for more information. Follow us on Linkedln: www.llnkedin.com/ company/the-technology-oartnership/

For further Information or queries please contact -

Shwet1 Munjal Vice President & Head - Corporate Communications Email: shwetamunjal@lueln.com